A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

This is a Phase 1, open label, parallel group study to investigate the effect of moderate and severe hepatic impairment on the plasma PK, safety, and tolerability after a single oral 100 mg dose of lorlatinib under fasted conditions.